Dr. Reddy's Laboratories Ltd. - Research Center
500124 DRREDDY Group (A) BSE data
Add to watchlist
| Results |
Quarterly
|
| Statement | |
| More |
Quarterly results in brief
(Rs crore)
| Mar' 24 | Dec' 23 | Sep' 23 | Jun' 23 | Mar' 23 | |
|---|---|---|---|---|---|
| Sales | 5,104.80 | 4,103.00 | 4,838.70 | 5,437.30 | 4,554.00 |
| Operating profit | 1,378.60 | 656.30 | 1,629.10 | 2,227.70 | 1,061.10 |
| Interest | 5.90 | 5.60 | 5.80 | 4.50 | 2.60 |
| Gross profit | 1,585.40 | 878.30 | 1,846.40 | 2,456.80 | 1,173.30 |
| EPS (Rs) | 62.04 | 28.49 | 71.50 | 98.40 | 40.36 |
Quarterly
results in details
| Mar' 24 | Dec' 23 | Sep' 23 | Jun' 23 | Mar' 23 | |
|---|---|---|---|---|---|
| Other income | 212.70 | 227.60 | 223.10 | 233.60 | 114.80 |
| Stock adjustment | -52.00 | -65.10 | -105.40 | -16.30 | 106.80 |
| Raw material | 907.70 | 818.70 | 751.20 | 813.90 | 854.10 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 779.50 | 782.30 | 783.70 | 740.20 | 765.10 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | 1,393.60 |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 2,065.00 | 1,910.80 | 1,780.10 | 1,671.80 | 369.20 |
| Provisions made | 26.00 | - | - | - | 4.10 |
| Depreciation | 246.20 | 246.40 | 245.80 | 237.20 | 236.70 |
| Taxation | 304.40 | 156.70 | 408.00 | 580.20 | 264.20 |
| Net profit / loss | 1,034.80 | 475.20 | 1,192.60 | 1,639.40 | 672.40 |
| Extra ordinary item | - | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 83.40 | 83.40 | 83.40 | 83.30 | 83.30 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 27.01 | 16.00 | 33.67 | 40.97 | 23.30 |
| GPM (%) | 29.81 | 20.28 | 36.48 | 43.32 | 25.13 |
| NPM (%) | 19.46 | 10.97 | 23.56 | 28.91 | 14.40 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis